Psilocin activates multiple pathways that may counteract neurodegenerative disease effects, potentially reducing symptoms and slowing disease progression. Through preclinical and clinical testing, we aim to assess the safety and efficacy of psilocin for a specific condition, paving the way for future regulatory approval as a pharmaceutical treatment.